In Segment A, members will acquire distinct doses and schedules of oral ABBV-744 tablet to establish Risk-free dosing program. Further members will probably be enrolled for the discovered monotherapy dosign regimen. In Segment B, contributors will receive oral ruxolitinib and ABBV-744 is going to be specified as "include-on" therapy. In https://abbv-744anditsimpactongen60135.therainblog.com/31148959/abbv-744-cancer-treatment-clinical-trials-an-overview